John Lynch, CEO, Merrion Pharmaceuticals
John Lynch is CEO of Merrion Pharmaceuticals a publicly listed, specialty pharmaceutical company engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection.
Merrion was established in 2003 to commercialise various technologies acquired from Elan Corporation, plc. It has developed two proprietary technology platforms; gastrointestinal permeations enhancement technology (GIPET®) and gastrointestinal retention systems (GIRES®) and the benefits of tablet form over injection are becoming increasingly apparent to the company as its technology develops and delivers.
John Lynch has extensive Pharmaceutical industry experience, with a 20-year career of achievement in many facets of the industry. In that time he has worked in senior positions in operations, business development, sales & marketing and finance.
Prior to joining Merrion, John was CEO of JML Healthcare which provided strategic consultancy to blue-chip big pharma as well as indigenous life science companies. Previous to that he had a 15 year career with Abbott Laboratories, Bayer Diagnostics Limited and Ernst & Young.
John received a BComm from University College Dublin and he is a member of the Innovation Taskforce established in 2009 by the Irish Government.
| John Lynch, CEO, Merrion Pharmaceuticals | |
 |
|
| Date | Wednesday 10 March 2010 |
| Venue | NovaUCD |
